A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

El-Khoueiry AB, Kim RD, Harris WP, Sung MW, Waldschmidt D, Cabrera R, Garosi VL, Ploeger BA, Zebger-Gong H, Brennan BJ, Wang YA, Mueller U, Weispfenning A, Seidel H, Coppieters S, Ishida TC, Galle PR.

Open source

DOI: 10.1097/hep.0000000000001585
Published: 2025-11-10
Container: Hepatology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hep.0000000000001585,
  title = {A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.},
  author = {El-Khoueiry AB and  Kim RD and  Harris WP and  Sung MW and  Waldschmidt D and  Cabrera R and  Garosi VL and  Ploeger BA and  Zebger-Gong H and  Brennan BJ and  Wang YA and  Mueller U and  Weispfenning A and  Seidel H and  Coppieters S and  Ishida TC and  Galle PR.},
  year = {2026},
  journal = {Hepatology},
  doi = {10.1097/hep.0000000000001585},
  url = {https://doi.org/10.1097/hep.0000000000001585}
}

RIS

TY  - JOUR
TI  - A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
AU  - El-Khoueiry AB
AU  -  Kim RD
AU  -  Harris WP
AU  -  Sung MW
AU  -  Waldschmidt D
AU  -  Cabrera R
AU  -  Garosi VL
AU  -  Ploeger BA
AU  -  Zebger-Gong H
AU  -  Brennan BJ
AU  -  Wang YA
AU  -  Mueller U
AU  -  Weispfenning A
AU  -  Seidel H
AU  -  Coppieters S
AU  -  Ishida TC
AU  -  Galle PR.
PY  - 2026
JO  - Hepatology
DO  - 10.1097/hep.0000000000001585
UR  - https://doi.org/10.1097/hep.0000000000001585
ER  -

APA

AB, E., RD, K., WP, H., MW, S., D, W., R, C., VL, G., BA, P., H, Z., BJ, B., YA, W., U, M., A, W., H, S., S, C., TC, I., & PR., G. (2026). A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.. Hepatology. https://doi.org/10.1097/hep.0000000000001585

Source records

europe-pmc · retrieved 2026-09-26T21:06:15.355Z